GoodRx announced a collaboration with Novo Nordisk to make all strengths of Ozempic® and Wegovy® pens available to eligible self-paying patients for $499 per month through the GoodRx platform, effective immediately. This initiative significantly lowers the price for two of the most in-demand GLP-1 medications nationwide.
This collaboration marks the first time Ozempic® has been made available to patients at this self-pay price, expanding access for millions who lack adequate insurance coverage. Demand for GLP-1 medications is at an all-time high, with almost 17 million people seeking savings and information on these drugs on GoodRx in the last year.
The partnership is a powerful example of how the GoodRx platform can deliver savings at scale, bridging gaps in insurance coverage and ensuring more people can access critical treatments. It represents a significant milestone in improving the affordability of authentic, FDA-approved medications for type 2 diabetes and obesity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.